Immunotherapy before surgery may shrink head and neck skin cancers, sparing vital structures

NCT ID NCT05929664

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 29 times

Summary

This study tests whether giving immunotherapy (cemiplimab alone or with fianlimab) before surgery can shrink advanced basal cell skin cancers of the head and neck. About 70 adults will receive 2 to 6 infusions before their operation. The goal is to see if the tumors respond enough to allow less extensive, function-preserving surgery. The study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Thomas Jefferson University Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Miami Health System

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

  • Vanderbilt University

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

Conditions

Explore the condition pages connected to this study.